Journal article · 2025 · Open access
Artificial intelligence in drug discovery and development: transforming challenges into opportunities
Discover Pharmaceutical Sciences, 1(1) · Published 2 June 2025 · DOI 10.1007/s44395-025-00007-3
In brief
“Artificial intelligence in drug discovery and development: transforming challenges into opportunities” is a 2025 journal article by Shashi Kant and 2 co-authors, published in Discover Pharmaceutical Sciences. OpenAlex counts 89 citations as of 15 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Discover Pharmaceutical Sciences.
- Citations
- 89
- Most cited in
- 2026 (67)
- Field-weighted impact
- 25.13
- References
- 113
- Authors
- 3
Abstract
Artificial intelligence (AI) has revolutionized drug discovery and development by accelerating timelines, reducing costs, and increasing success rates. AI leverages machine learning (ML), deep learning (DL), and natural language processing (NLP) to analyze vast datasets, enabling the rapid identification of drug targets, prediction of compound efficacy, and optimization of drug design. It accelerates lead discovery by predicting pharmacokinetics, toxicity, and potential side effects while also refining clinical trial designs through improved patient recruitment and data analysis. This review highlights the diverse benefits of AI in drug development, including enhanced efficiency, greater accuracy, and minimized risks. It also discussess critical challenges, such as data quality, model interpretability, and regulatory hurdles. Future advancements in AI-powered drug discovery will require a focus on improving data standardization, fostering transparency in AI model development, and strengthening collaboration between AI researchers and pharmaceutical experts. By addressing these challenges, AI holds the potential to transform the healthcare landscape by delivering safer, more effective, and more affordable medicines to patients.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kant, S., Deepika, & Roy, S. (2025). Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences, 1(1). https://doi.org/10.1007/s44395-025-00007-3
MLA 9
Kant, Shashi, et al. “Artificial intelligence in drug discovery and development: transforming challenges into opportunities.” Discover Pharmaceutical Sciences, vol. 1, no. 1, 2025. https://doi.org/10.1007/s44395-025-00007-3.
Chicago
Kant, Shashi, Deepika, and Saheli Roy. 2025. “Artificial intelligence in drug discovery and development: transforming challenges into opportunities.” Discover Pharmaceutical Sciences 1 (1). https://doi.org/10.1007/s44395-025-00007-3.
Harvard
Kant, S., Deepika and Roy, S. (2025) ‘Artificial intelligence in drug discovery and development: transforming challenges into opportunities’, Discover Pharmaceutical Sciences, 1(1). doi:10.1007/s44395-025-00007-3.
IEEE
S. Kant, Deepika, and S. Roy, “Artificial intelligence in drug discovery and development: transforming challenges into opportunities,” Discover Pharmaceutical Sciences, vol. 1, no. 1, 2025, doi: 10.1007/s44395-025-00007-3.
BibTeX
@article{kant2025artificial,
title = {{Artificial intelligence in drug discovery and development: transforming challenges into opportunities}},
author = {Kant, Shashi and Deepika and Roy, Saheli},
journal = {Discover Pharmaceutical Sciences},
year = {2025},
volume = {1},
number = {1},
doi = {10.1007/s44395-025-00007-3},
url = {https://doi.org/10.1007/s44395-025-00007-3}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 21 | |
| 2026 | 67 |
Its field-weighted citation impact is 25.13: it has been cited 25.13 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- artificial intelligence in drug discovery
- drug development
- machine learning
- deep learning
- natural language processing
- drug target identification
- pharmacokinetic prediction
- toxicity prediction
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Kant, S., Deepika, & Roy, S. (2025). Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences, 1(1). https://doi.org/10.1007/s44395-025-00007-3
How many times has this paper been cited?
89 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Discover Pharmaceutical Sciences.
Who wrote this paper?
Shashi Kant, Deepika, Saheli Roy.
What is the DOI of this paper?
10.1007/s44395-025-00007-3. The permanent link is https://doi.org/10.1007/s44395-025-00007-3.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.